Navigation Links
Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
Date:1/15/2009

of the Law of 3 July 2008, the AFEP/MEDEF code, as amended, will be the benchmark the Group will refer to in the preparation of the Chairman of the Board's report on corporate governance, which will explain and specify the rules implemented by the Group.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 20% of its sales in gross resources to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2008, Stallergenes had sales of EUR 170.9 million and provided desensitization treatments to more than 500,000 patients.

    Euronext Paris (Compartment B)
    SBF 120.
    ISIN Code: FR0000065674
    Reuters Code: GEN.PA
    Bloomberg Code: GEN.FP

Additional financial information is available at http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
2. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
3. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
4. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
5. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
6. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
7. BIO 2008: Germany on Cutting Edge in Biomanufacturing
8. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
9. Commencement 2008: Student innovation could improve data storage, magnetic sensors
10. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
11. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
(Date:12/17/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... changes to Martine Rothblatt , Ph.D,s compensation program. ... United Therapeutics announced the promotion of Roger Jeffs ... David Zaccardelli , Pharm.D. to Executive Vice President ... Dr. Rothblatt,s title will change from Chairman and Chief ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that the ... PVM technology , is now available. The new ... continuously captures high-resolution images under a wide range ... a report pairing the most relevant images to ... compelling blend of high resolution images and trend ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... eight port right-angle BNC connectors to its product line. The ... for applications where a number of single or dual port BNC ... ... (PRWEB) April 29, 2009 -- Regal Electronics has added four, six ...
... - Strong Focus on the Markets of Pharma & Life Science ... of EUR0.40 per Share , The Annual ... per share following the record year in 2008. , ... results.,Gerresheimer achieved sales of EUR1.06 billion (prior year EUR957.7m) and,operating results ...
... MSEDMONTON, April 29 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), ... today announced that Mr. Kevin Giese, President and CEO, will ... development of a world class technology sector" as part of ... WHEN: Monday May 4th at ...
Cached Biology Technology:Regal Introduces Four, Six and Eight Port Filtered and Un-Filtered Right Angle BNC Connectors 22008 a Record Year for Gerresheimer 2BioMS Medical to present at Alberta Economic Forum in Geneva 2
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... plague belongs to a virulent family of bacteria called ... for food poisoning. These bacteria insert into their host ... -- among other things -- disrupting the cells' normal ... cell's internal skeleton. Now, a study published by Rockefeller ...
... the Translational Genomics Research Institute (TGen) in Phoenix, ... discover a gene--called Kibra--associated with memory performance in ... develop new medicines for memory-based diseases such as ... better understanding of how memory works at the ...
... low birth weights tend to have a much lower quality of ... a study published in the latest issue of the UK-based Journal ... birth weights of 1500g or less and compared them with a ... quality of life when it came to physical, emotional, cognitive and ...
Cached Biology News:A wolf in sheep's clothing: Plague bacteria reveal one of their virulence tricks 2Affymetrix 500K array used to identify memory gene 2Very low birth weight linked to reduced quality of life in pre-school children 2
... PCR Spots, Oligo Spots and complementary RNA ... microarray experiments. Use for glass array printing ... for reverse transcription, cDNA labeling, hybridization stringency ... Control PCR Spots and Oligo Spots, ...
Kit for Detection of Mitochondrial Membrane Potential...
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
MOUSE ANTI HUMAN C-MYC aa171-188...
Biology Products: